Abstract: A system for controlling an air heat exchanger of a vehicle includes an information collector which collects environmental information including a current speed of a vehicle, a desired air mass flow rate, and an ambient temperature. A storage stores the environmental information therein. A controller calculates a driving load and a cooling load in accordance with the environmental information and calculating a control amount of an air heat exchanger, at which a cost function that is a sum of the driving load and the cooling load is minimum.

Abstract: A system for controlling an air heat exchanger of a vehicle includes an information collector which collects environmental information including a current speed of a vehicle, a desired air mass flow rate, and an ambient temperature. A storage stores the environmental information therein. A controller calculates a driving load and a cooling load in accordance with the environmental information and calculating a control amount of an air heat exchanger, at which a cost function that is a sum of the driving load and the cooling load is minimum.

Abstract: A vehicular thermal management system includes: an indoor-air-conditioner disposed in a first vehicle body having a passenger space and including a compressor, a first condenser, an evaporator, a blower, and a refrigerant line; and a component-air-conditioner disposed in a second vehicle body combinable with the first vehicle body and including an electrical component line for cooling an electrical component of the vehicle and a first battery line for cooling a high-voltage battery including a chiller which extends toward the first vehicle body to be disposed behind the evaporator when the first vehicle body is combined with the second vehicle body.

Abstract: A vehicular thermal management system includes: an indoor-air-conditioner disposed in a first vehicle body having a passenger space and including a compressor, a first condenser, an evaporator, a blower, and a refrigerant line; and a component-air-conditioner disposed in a second vehicle body combinable with the first vehicle body and including an electrical component line for cooling an electrical component of the vehicle and a first battery line for cooling a high-voltage battery including a chiller which extends toward the first vehicle body to be disposed behind the evaporator when the first vehicle body is combined with the second vehicle body.

Abstract: An integrated thermal management circuit for a vehicle is introduced, which includes a refrigerant line on which a refrigerant flows into the compressor; a battery cooling line making a cooling water circulate between a battery and a battery radiator or between the battery and the battery chiller; an electric cooling line making the cooling water circulate between an electronic driving unit and an electric radiator or between the electronic driving unit and the electric chiller; and a chiller control valve provided at an upstream point of the electric chiller and the battery chiller on the chiller line, and making the refrigerant discharged from the external heat exchanger flow into the electric chiller or the battery chiller.

Abstract: An integrated thermal management circuit for a vehicle includes a refrigerant line that causes a refrigerant to flow through a compressor, an interior condenser of an interior air conditioning device, and an exterior condenser outside the vehicle. The circuit causes the refrigerant discharged from the condenser to pass through an integrated chiller or an evaporator of the air conditioning device and to be introduced into the compressor. The circuit includes: a first cooling line causing a cooling water to circulate between a high voltage battery and a first radiator or between the high voltage battery and the integrated chiller; a second cooling line causing the cooling water to circulate between an electronic drive unit and a second radiator or between the electronic drive unit and the integrated chiller; and a bypass line provided in the first cooling line.

Abstract: The present invention relates to an automatic in vitro diagnostic apparatus capable of automatically performing a series of examination processes including a pretreatment process for specific components included in a biological sample such as blood and urine. The apparatus of the present invention comprises a base frame 104; a cuvette tray 110 movable back and forth on the base frame 104, for mounting cuvette holders 10 accommodating a plurality of cuvettes arranged thereon alongside each other; a tube tray 120 movable back and forth on the base frame, for mounting tube holders 20 accommodating a plurality of sample tubes containing samples thereon; and a sampling operation unit 500 movable left and right on the base frame 104, for mixing a sample contained in the sample tube with a reagent, and dropping the mixed solution onto an analysis strip provided in the cuvette.

Abstract: A vehicle thermal management circuit includes a refrigerant line configured to cause refrigerant to flow in the order of a compressor, an indoor condenser and an outdoor heat exchanger of an indoor air-conditioning apparatus, a battery cooling line configured to circulate cooling water between a battery and a battery radiator or between the battery and a chiller unit, an electric part cooling line configured to circulate cooling water between an electronic driving unit and an electric part radiator or between the driving unit and the chiller, and an accumulation unit located at an upstream point of the compressor on the refrigerant line, includes an expansion valve and a refrigerant heater, and is configured to receive the refrigerant discharged from the chiller or the evaporator and provide the received refrigerant to the compressor or to expand or heat the refrigerant and provides the expanded or heated refrigerant to the compressor.

Abstract: Provided is a novel pyrrolopyridine compound represented by Chemical Formula I, a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and to a method for preparing the same. A compound represented by Chemical Formula I shows high selectivity and antiviral activity against human immunodeficiency virus (HIV), with low toxicity; therefore, it is useful as a therapeutic agent for viral infection, in particular, HIV infection.

Abstract: Provided is a novel pyrrolopyridine compound represented by Chemical Formula I, a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and to a method for preparing the same. A compound represented by Chemical Formula I shows high selectivity and antiviral activity against human immunodeficiency virus (HIV), with low toxicity; therefore, it is useful as a therapeutic agent for viral infection, in particular, HIV infection.

Abstract: The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: Provided are heterocyclic compounds, having effects of treating and preventing inflammatory diseases and treating skin wounds, and particularly, exhibiting effects of recovering disrupted skin barriers, mitigating inflammation, and pruritus. Also, a composition containing the compound as an effective component can be used to mitigate various inflammatory diseases and protease activated receptor-2 (PAR-2)-overexpressed diseases, and can be particularly used as a composition having an anti-inflammatory function in inflammatory skin diseases including atopic dermatitis and the like, by inhibiting PAR-2 activity.

Abstract: The heterocyclic compound according to the present invention may treat and prevent inflammatory diseases and heal skin wounds, and particularly, have effects of recovering damaged skin barrier, reducing inflammation and pruritus in inflammatory skin diseases. In addition, the composition containing the compound according to the present invention as an active ingredient may be used to alleviate various inflammatory diseases and diseases in which PAR-2 is excessively expressed, and particularly, the composition may inhibit activity of PAR-2 in skin, such that the composition may be used as a composition having anti-inflammatory function in inflammatory skin diseases including atopic dermatitis, or the like.

Abstract: Provided are heterocyclic compounds, having effects of treating and preventing inflammatory diseases and treating skin wounds, and particularly, exhibiting effects of recovering disrupted skin barriers, mitigating inflammation, and pruritus. Also, a composition containing the compound as an effective component can be used to mitigate various inflammatory diseases and protease activated receptor-2 (PAR-2)-overexpressed diseases, and can be particularly used as a composition having an anti-inflammatory function in inflammatory skin diseases including atopic dermatitis and the like, by inhibiting PAR-2 activity.